Microbot Medical Bolsters leadership ahead of LIBERTY® commercial launch

Microbot Medical Inc. (Nasdaq: MBOT), the developer of the innovative LIBERTY® Endovascular Robotic System, has announced the appointment of Ms. Michal Ahuvia to the newly established role of Director of Operations. In her new role, Ms. Ahuvia will lead efforts to ramp up production and enhance operational efficiency as the company gears up for the anticipated commercial launch of LIBERTY® in Q2 2025. She will report to Simon Sharon, General Manager and Chief Technology Officer at Microbot Medical.

With over 20 years of expertise in operations, Ms. Ahuvia has an impressive track record in process optimization, material planning, logistics, production, and supply chain management. She has held key operational roles at renowned organizations, including Philips Healthcare, Nanomotion, XACT Robotics, and Jordan Valley. She holds a B.Sc. in Industrial Engineering and Management from Ben-Gurion University, bringing both technical knowledge and practical expertise to her new position.

Harel Gadot, Chairman, CEO, and President of Microbot Medical, emphasized the strategic importance of Ms. Ahuvia’s appointment, stating, “Ramping production of LIBERTY® in the most efficient way is critical to our commercial strategy and future success. Michal brings a wealth of knowledge and experience, and I am confident in her ability to execute our operational plans and achieve our commercial objectives.”

Ms. Ahuvia’s addition strengthens Microbot Medical’s focus on streamlining manufacturing and operations processes, ensuring the LIBERTY® Endovascular Robotic System meets market demand as the company approaches its groundbreaking launch.